Phytotherapy for benign prostatic hyperplasia
- 1 August 2002
- journal article
- review article
- Published by Springer Nature in Current Urology Reports
- Vol. 3 (4), 285-291
- https://doi.org/10.1007/s11934-002-0050-3
Abstract
Phytotherapy has become a more popular treatment option among American men with benign prostatic hyperplasia (BPH). The most popular herbal agent is saw palmetto (Serenoa repens), which is derived from the berry of the American dwarf palm tree. Pygeum africanum and beta-sitosterol are also used by many patients with BPH, either alone or in combination with saw palmetto. A significant limiting factor to our understanding of the use and effectiveness of phytotherapy is the lack of standardization of these products. Despite this lack of standardization and the variation in results that may be seen with herbal products, there is growing evidence from well-conducted clinical trials that phytotherapeutic agents may lead to subjective and objective symptom improvement beyond a placebo effect in men with BPH. In addition, histologic evidence has been presented demonstrating that saw palmetto causes atrophy and epithelial contraction within the prostate gland. Overall, it is likely that herbal therapy will continue to be used by a growing number of Americans to treat a variety of ailments. Physicians should attempt to remain open-minded regarding alternative approaches and educate themselves so that they may counsel patients in an informed and credible fashion.Keywords
This publication has 40 references indexed in Scilit:
- Treatment of symptomatic benign prostatic hyperplasia with β‐sitosterol: an 18‐month follow‐upBJU International, 2000
- Antiproliferative Effect of Pygeum Africanum Extract on Rat Prostatic FibroblastsJournal of Urology, 1997
- Effects of Tadenan Pretreatment on Bladder Physiology and Biochemistry Following Partial Outlet ObstructionJournal of Urology, 1996
- Protective Effect of Tadenan of Bladder Function Secondary to Partial Outlet ObstructionJournal of Urology, 1996
- Placebo-Controlled Evaluation of the Efficacy and Tolerability of Permixon® in Benign Prostatic Hyperplasia after Exclusion of Placebo RespondersClinical Drug Investigation, 1995
- Results of Treatment with Pollen Extract (CerniltonR N) in Chronic Prostatitis and ProstatodyniaBritish Journal of Urology, 1993
- Treatment of Outflow Tract Obstruction due to Benign Prostatic Hyperplasia with the Pollen Extract CerniltonBritish Journal of Urology, 1990
- The Value of Permixon in Benign Prostatic HypertrophyBritish Journal of Urology, 1986
- Inhibition of androgen metabolism and binding by a liposterolic extract of “serenoa repens B” in human foreskin fibroblastsJournal of Steroid Biochemistry, 1984
- Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostateJournal of Steroid Biochemistry, 1984